JBIO
Jade Biosciences, Inc.
$20.95
-1.53 (-6.81%)
At close · Jul 10
Market Cap
$1.03B
Shares
49,359,875
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
Net Income
-$127.41M
-83%
FY2025
Diluted EPS
-$3.19
+96.3%
FY2025
Operating Cash Flow
-$94.69M
-33%
FY2025
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|---|
| $109.15M | $93.12M | $53.19M | $64.22M | $38.62M | $14.99M | $7.94M | |
| $24.45M | $20.42M | $21.41M | $17.19M | $14.62M | $8.04M | $949K | |
| $133.6M | $113.54M | $74.6M | $81.41M | $53.24M | $23.02M | $8.89M | |
| -$133.6M | -$113.54M | -$74.6M | -$81.41M | -$53.24M | -$23.02M | -$8.89M | |
| — | — | — | — | — | — | $75K | |
| $4.07M | -$13.81M | $5.02M | $5.94M | $1.75M | $62K | -$722K | |
| — | -$127.35M | -$69.57M | -$75.47M | -$51.49M | -$22.96M | -$9.61M | |
| — | $58K | $55K | $56K | $25K | $3000 | — | |
| -$129.61M | -$127.41M | -$69.63M | -$75.52M | -$51.51M | -$22.96M | -$9.61M | |
| — | -$100.14M | -$69.63M | -$75.52M | -$51.51M | -$22.99M | -$9.76M | |
| -$129.95M | -$127.28M | -$69.76M | -$74.82M | -$51.92M | -$23.02M | -$9.61M | |
| USD/shares | — | -$3.19 | -$85.40 | -$100.45 | -$73.50 | -$65.45 | — |
| USD/shares | — | -$3.19 | -$85.40 | -$100.45 | -$73.50 | -$65.45 | — |
| shares | — | 31.36M | 816.63K | 752.33K | 699.2K | 351.25K | 6920.9143 |
| shares | — | 31.36M | 816.63K | 752.33K | 699.2K | 351.25K | 6920.9143 |
Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against the industry, and each ratio recomputed as of past filing dates.
Valuation
EV/Revenue
—
Biotechnology median 8.05×
EV/EBIT
—
Biotechnology median 25.73×
P/E (TTM)
2.51×
Biotechnology median 7.68×